Synopsis

Source of validity: Scientific
Rating (out of 5): 2

C-Phycocyanin, a pigment-protein complex derived from Spirulina and other cyanobacteria, has been investigated in preclinical studies for potential cardiovascular benefits. The majority of evidence comes from in vitro and animal research, where C-Phycocyanin has demonstrated antioxidant, anti-inflammatory, and anti-apoptotic properties. These effects suggest a possible role in protecting cardiovascular tissues from oxidative stress and inflammation—both significant contributors to cardiovascular disease (CVD) pathology. Some studies have shown that C-Phycocyanin can reduce lipid peroxidation, improve endothelial function, and attenuate cardiac damage in animal models of myocardial injury or atherosclerosis. However, there is a lack of robust human clinical trials directly evaluating C-Phycocyanin’s efficacy in preventing or treating cardiovascular disease. Most human data relate to Spirulina as a whole, which contains C-Phycocyanin among other bioactive compounds, making it difficult to attribute observed effects specifically to C-Phycocyanin. Thus, while mechanistic and animal evidence supports the plausibility of cardiovascular benefits, direct clinical validation is minimal. In summary, the use of C-Phycocyanin for cardiovascular disease is supported by early-stage scientific research, but human clinical evidence is insufficient. Further studies, especially well-designed clinical trials, are needed to confirm its therapeutic value in this context.

More about C-Phycocyanin
More about Cardiovascular Disease

Other ingredients used for Cardiovascular Disease

Other health conditions supported by C-Phycocyanin

Products containing C-Phycocyanin